About Us

Who We Are

Established in 2014 as a joint venture between Abu Al Haj Family and Al Faisaliah Group, Axantia develops, manufactures, markets, and distributes high-quality branded generic pharmaceuticals and under-licensed products in 20 countries across the Middle East, Africa, and the CIS.

With the company’s immediate growth, its commitment to meet the healthcare needs of patients becomes even stronger. By providing a broad spectrum of high quality, effective, and affordable pharmaceutical products, Axantia continues to leap towards the betterment of lives one day at a time.

Our Business

Axantia was established to deliver high-quality and affordable medicines, exploit scale, and foresee and respond to new opportunities and risks.

Our subsidiaries – Pharma International Company in Jordan and Med City Pharmaceutical Industries in Saudi Arabia are supported by functional organizations with different manufacturing lines to deliver a broad portfolio covering all major therapeutic areas.

Research and development (R&D):

Development of

  1. Oral solid dosage forms
    • Immediate release formulation for General Formulation and Cephalosprins including:
      • Tablets and capsules
      • Dry suspension
    • Modified release formulations:
      • Enteric coated tablets
      • Extended release tablets
  2. Oral liquid forms such as syrups
  3. Cephalosporin powder for injection
  4. Semi solid forms:
    • Ointment
    • Creams

Machinery

  1. Lab scale:
    • Wet granulation suite
    • Tableting
    • Toating
  2. GMP Pilot scale:
    • Wet granulation suite
    • Dry granulation compaction.
    • Tableting monolayer and bilayer
    • Capsule filling
    • Coating
  3. Analytical Research capability:
    • Develop and validate test methods according to latest ICH , EMA and FDA guidelines.
    • Stability testing according ICH guidelines
    • Photostability studies according to ICH guidelines.
    • UHPLC systems with enterprise software solution fully compliant to 21 CFRpt.11
    • Automated dissolution sampling

1. General Formulations Plant

PIC’s main plant covers a total area of about 9,300 m2 that is equipped to produce the following dosage forms:

  • Tablets, Capsules
  • Liquids
  • Creams, Ointment and gels
  •  Suppositories
  • Medicated shampoos


2.
Cephalosporins Plant

IC’s Cephalosporin plant (Unit I&II) covers a total area of 5,000 m2 that is equipped to produce the following dosage forms:

  • Tablets
  • Capsules
  • Dry Suspensions
  • Injections


3. GMP Certificates

  • Jordan
  • Saudi Arabia
  • Ukraine (PICs)
  • GCC
  • Iraq
  • Sudan
  • Yemen
  • Uganda
  • Tanzania
  • Chad
  • Ethiopia
  • Lebanon

4. ISO Certificates

  • 9001
  • 14001
  • 27001:2013

1. General Formulations

Under construction facility that covers a total area of 9,000 m2, will be equipped to produce the following dosage forms:

  • Tablets
  • Capsules
  • Sachets
  • Creams, Ointments, and Gels

 

2. Med City Pharma has obtained a GMP Certificate from SFDA for secondary packaging of Cephalosporins and GF products

3. Future plans include having an injectable plant in MD

Our Values

Success: Our pursuit is to constantly achieve and accomplish visions and goals we have set. That is why we take a closer look at things, ask questions, and always think ahead.

Accountability: We will always take full responsibility of our tasks and duties, along with their consequences. At Axantia, we honor our commitment to stakeholders and ensure that no task or goal entrusted to us will ever be consciously taken for granted.

Performance: We at Axantia draw on more than savvy and skills; our core values fuel us to be high performers and to make the right decisions. Recognizing that integrity, quality, and leadership make up the company’s soul, we have found the drive to help us perform better and succeed longer.

Quality: Keeping in mind that consumers stake their wellbeing on the quality of our products drives us to produce work of high standard – all the while paying attention to every detail and completing all tasks punctually.

Integrity: Our company, along with our employees, strive to serve as role models by upholding our organizational rules – behaving in public as we would in private by contributing to an environment that does not tolerate ethical deviation. By putting short-term gains in the backburner, the company’s long-term reputation is remains paramount.

Collaboration: Through collaboration and cooperation among our people by championing high performing teams with variance and inclusion, we are able to increase drive and commitment, contributing to the motivation and retention of our employees.

Core values

Our Management


With the objective of increasing access to high-quality, affordable medicines, we at Axantia are constantly thinking outside the box and challenging ourselves by boosting our associates’ skills and building a diverse workforce with talented leaders who hold extensive experience in the pharmaceutical industry.

Rula Al-Qassem With 25 years of experience under her belt, Rula AlQasem directs Pharma International Company (PIC) and Med City Pharma to achieve rapid growth and execution in support of the business’ expansions goals. Serving in several leadership roles with Astra Zeneca including Head of Market Access and Government Affairs in the MEA region and as President of MENA, AlQasem lead the organization to become one of the top three companies in the market. Additionally, acquiring an executive management role with Elli Lilly & Co., she focused her time on guiding the organization and building focused teams. AlQasem holds a BSc in Pharmacy from the University of Jordan, as well as an MBA in Marketing and Leadership from the University of Columbia in New York. Rula AlQasem Chief Executive Officer Emad Kakish With 20 years of experience in Pharmaceutical industry and in audit field work at Deloitte and Mazars- in Jordan and UAE-, Emad possesses great business acumen across several areas such as debt restructuring, M&A, equity deals, financial modeling, feasibility studies, financial planning, setting KPIs, management of financial risks and ERP implementations. Emad holds a bachelor degree in accounting from University of Jordan. He is also a Certified Public Accountant (CPA) with many training courses in leadership, time management, PMP, CMA and IFRS updates. Emad manages Finance and IT departments to help achieving Axantia’s vision and mission. He is ambitious to be part of setting Group’s value creation plan. He believes in achieving goals through determination and dedication of all stakeholders. Emad Kakish Chief Financial Officer Raed Smadi With over 22 years of experience in Human Resources in reputable local and regional companies in Jordan, Raed Smadi joined PIC in 2017 as the Executive Director for Human Resources. He holds a Master’s Degree in Systems and Industrial Engineering from the University of Wales and a BSc in Industrial Engineering from the University of Jordan. Smadi has served in numerous industries in Senior Leadership HR positions including Aviation/Airlines, Logistics and Supply, in addition to Pharmaceutical Manufacturing industries. Raed Smadi Executive Director Human Resources Musaab Zeidan Carrying over 20 years of experience in the pharmaceutical industry in the MENA region, Musaab Zedan started his career as a Medical Representative at GlaxoSmithKline. He maintained different levels of responsibilities including the role of Supervisor, Sales Manager, and Country Manager; eventually becoming the Regional Director. In 2015, Zedan joined PIC as the Regional Director in Iraq, eventually landing the position of Commercial Director (MENA). With a Bachelor’s degree in Pharmacy from Damascus University and an MBA from Arab Academy of Science and Technology, along with his broad experience in sales and marketing, we have no doubt that Zedan will drive the commercial team to achieve our vision and goals. Musaab Zeidan Executive Director Commercial Mohammed Arafeh With more than 26 years of diverse experience, Mr. Mohamed Arafeh has recently joined Axantia on as the General Manager for KSA Mr. Arafeh holds his BSc in pharmacy from King Saud University in Riyadh, Saudi Arabia. During his profession years, He started his career at one of the reputable international companies, leading the marketing department at AstraZeneca – regional office in Brussels, Belgium. He then led his team as Country President at AZ in Saudi Arabia where he built many strong partnerships which had holistically enriched and developed the business performance. On January 2018, he was appointed at Dar Al Dawa as the General Manager in which he led the transformation process by creating a high-performance culture that allowed the employment of new frameworks to be both successful and profitable. As a visionary leader, Arafeh believes that one of the most core values in any business is the necessity of collaboration and teamwork to drive success. Mohammed Arafeh General Manager KSA Zakiya Kurdi Zakiya Kurdi is a pharmaceutical and biotechnology professional with 30 years of pharmaceutical industry experience possessing strong technical, developmental, and managerial experience. During her position as Licensing Director at The Jordanian Pharmaceutical Manufacturing Co., Kurdi was responsible for business development, regulatory and licensing activities, and technology transfer – successfully concluding and executing licensing out agreements with partners in different countries counting UAE, Oman, Iraq, Syria, Morocco, Bosnia, and Herzegovina. Additionally, Kurdi led several technology transfer projects all the while meeting objectives to register the product subject to technology transfer process. Prior to that, she served as the Quality Control Manager and Deputy Technical Director under the same company. Kurdi holds BSc in Pharmacy from Yarmouk University in Jordan and PhD in Biopharmaceutical Science, Drug Delivery System from University of Greenwich/ UK. Kurdi currently holds the title of Operation Executive Director of Axantia. Zakiya Kurdi Executive Director Operations Wael Abu El Rub With more than 20 years of diverse experience in Pharmaceutical sector, Wael Abu El Rub had joined Axantia on March 2019. Wael holds BSc in pharmacy from APU- Jordan, and obtained accredited certificates from high reputable institutions such as PMP and Mini MBA from MIT.  During his profession, Wael had accomplished many successful projects within multinational and local pharmaceutical companies in the region, having that said; including roles at Hikma Corporate (covering Projects in both USA and MENA). He then headed the Technical Operation Team in TABUK Pharmaceuticals-KSA in which he had excelled in achieving a measurable growth in revenues while building a robust technical quality culture in operations. He is leading Med City Pharma KSA site for Axantia as the Plant Director, his forceful directions guided Med City Pharma project towards completing the infrastructure and creating strong systems and functions exploiting the most international pharmaceutical standards and internal guidelines. Wael Abu El Rub Director Plant Med City Pharma Dana Naji Prior to joining PIC in July 2015 as RA Director, Dana Naji was the Head of Drug Regulatory Affairs in Astra Zeneca - Levant for 8 years, claiming responsibility of regulatory strategy design and roll out plans; thereupon reflecting company priorities. Her role also included enforcing pricing strategies in accordance with local regulations and company profitability, in addition to networking with influential health officials and various stakeholders. Earlier in her career, Naji was the Regulatory Affairs Manager at Jardaneh for 9 years, where she was responsible for all regulatory submissions and tender pricing and logistics. Naji holds a BSc in Pharmacy from the University of Jordan and an MBA from New York Institute of Technology with a double major in HR and International Business. Dana Naji Executive Director Regulatory and Pricing Abdullah Othman Before joining Axantia as R&D Director in 2016, Abdallah Othman was the Corporate Quality and Senior Compliance Manager at Hikma Pharmaceuticals, conducting quality audits on suppliers and contract manufacturers, CROs and Hikma subsidiaries focusing on sterile manufacturing. He successfully administered around 100 internal and external audits in different countries including Europe, India, Taiwan, Japan, Middle East, and USA. With over 18 years of experience in the pharmaceutical industry to this day, Abdallah currently holds the title of Quality Director of Axantia. Abdullah Othman Executive Director Quality Waheed Al Oran Waheed L. Al Oran had Joined Axantia on November 2016 as the Marketing Director for the Specialty Care Unit. He holds a master degree in Healthcare Management from the Royal College of Surgeons in Ireland (RCSI) and had acquired his Bachelor degree in pharmacy from the Applied Science University in Amman, Jordan. During his past eighteen years, while he was working for different multinational pharmaceutical companies such as GlaxoSmithKline, Novartis and Hikma Pharmaceuticals; he also handled different positions in sales and marketing. Throughout his career, he participated and oversaw several corporate projects and successfully led regional roles in Marketing Management, Sales Management, Strategic Planning and Market Access. Before Joining Axantia, Mr. Al Oran led the planning and commercial operations of Hikma’s hospital and specialty care businesses in the MENA region including Injectable, Oncology and Transplantation units. Waheed Al Oran Director Business Development & Strategy Mohammed Khalaf Eng. Mohammad Khalaf has recently joined Axantia on September 2020 as Corporate Supply Chain Director. With robust experience in supply & demand planning , logistics , procurement , warehousing, production and retail operations; he will embrace and successfully manage the Supply Chain department employing his best business practices that proven to be efficient and reducing the operation costs whilst increasing performance.    Mohammad, had been managing several supply chain departments at well-established regional and local pharmaceutical companies and he holds a BA degree in Industrial Engineering and a Master degree in Business Administration and Total Quality Management from the University of Bradford UK. Along with various international certificates that Mohammad holds, he is a Certified Six Sigma Black Belt and a Certified Supply Chain Professional. Mohammed Khalaf Director Supply Chain Shadi AbuHamra With more than 21 years of experience, Shadi AbuHamra, Axantia for Senior Manager of Research and Development department. As an industrial pharmacist who graduated from the Jordan University of Science and Technology, he started his career as a Production Supervisor at Al-Razi Pharmaceutical Company. Afterwards Shadi was able to acquire different managerial positions in the fields of production and R&D at multi-regional and local pharmaceutical companies. He then moved to Dar Al Dawa. Before joining Axantia, he was acting as the Research and Development Senior Manager at AL-Taqaddom Pharmaceuticals Industry Company. Being equipped with such extensive experience, Shadi will bring lots of expertise towards driving Axantia to maximize product developments . Shadi AbuHamra Director Research and Development Ahmad Zoabi Following a 20-year track record of success, Ahmed Zu’bi is Axantia’s Legal Counsel and Company Secretary. His extensive knowledge in the legal profession include corporate and commercial matters, contract drafting, construction, and project financing. Zu’bi also has a strong background in litigation and arbitration. Qualifications & Professional Affiliations:
- Bachelor’s degree in Law, Jordan University, Jordan
- Master’s degree LLM in International Economic Law, Warwick University, UK
- Master’s degree LLM in International Business Law, University of Manchester, UK
- Jordan Bar Association
Ahmed M. Zu’bi Legal Counsellor

Partnership

Being one of the top 10 key players in the generic pharmaceutical industry in the MENA region, coupled with its in-depth experience and expertise in manufacturing and marketing, Axantia is well-placed to be the partner of choice for companies looking to establish business in this part of the world.

This is for the following reasons:

• Strong local operational infrastructure and expertise across MENA markets
• Financially strong to fund growth and development
• High investment in infrastructure, product development, and human capital
• Continuous growth

We partner with selected pharmaceutical companies to provide access to finished products across the MENA region.